Evidence map›Paper›PMID 39575246›Full record

ArticleFrontiers in immunology2024

Human CD34

Giovanna Fiore, Wolfgang Weckwarth, Kerstin Paetzold, Llucia Albertí Servera, Manuela Gies, Jakob Rosenhauer, Martina Antoniolli, Sina Nassiri, Stephan Schmeing, Steffen Dettling and 5 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. How experimental models have unlocked hidden mechanisms of hypersensitivity pneumonitis.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Giovanna FioreRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Wolfgang WeckwarthRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Kerstin PaetzoldRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Llucia Albertí ServeraRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
Manuela GiesRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Jakob RosenhauerRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Martina AntoniolliRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Sina NassiriRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
Stephan SchmeingRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
Steffen DettlingRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Bhavesh SoniRoche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Zurich, Switzerland.
Meher MajetyRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Anne B KrugInstitute for Immunology, Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, Germany.
Sabine HovesRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Monika Julia WolfRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Plasmacytoid dendritic cells (pDCs) are capable of triggering broad immune responses, yet, their scarcity in blood coupled to their reduced functionality in cancer, makes their therapeutic use for Methods: We designed an Results: Here, we report an Discussion: This study highlights CB-pDCs as surrogates for primary pDCs to investigate their biology and for their potential use as cell therapy in cancer.

Indexed as

Antigens, CD34Cell DifferentiationDendritic CellsCells, CulturedCoculture TechniquesFetal BloodGranulocyte-Macrophage Colony-Stimulating FactorHematopoietic Stem CellsHumansImmunotherapyNeoplasmsTumor MicroenvironmentAntigens, CD34Granulocyte-Macrophage Colony-Stimulating Factorcancer immunotherapyDC vaccinationdendritic cell differentiationhematopoietic stem cells (HSCs)humanplasmacytoid dendritic cells (pDCs)

Identifiers

PMID39575246
PMCPMC11578708

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.